JW Shinyak Corporation Stock

Equities

A067290

KR7067290007

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
1,788 KRW +0.51% Intraday chart for JW Shinyak Corporation +2.76% -27.90%
Sales 2022 103B 74.77M Sales 2023 104B 75.88M Capitalization 126B 91.54M
Net income 2022 1.4B 1.02M Net income 2023 -37.36B -27.2M EV / Sales 2022 1.81 x
Net Debt 2022 10.61B 7.73M Net Debt 2023 9.04B 6.58M EV / Sales 2023 1.29 x
P/E ratio 2022
127 x
P/E ratio 2023
-3.36 x
Employees 231
Yield 2022 *
-
Yield 2023
-
Free-Float 70.46%
More Fundamentals * Assessed data
Dynamic Chart
JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
JW Shinyak Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
JW Shinyak Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
JW Shinyak Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
JW Shinyak Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
JW Holdings Corporation agreed to acquire additional 5.55459% stake in JW Shinyak Corporation for KRW 11.6 billion. CI
JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
JW Shinyak Corporation cancelled the acquisition of an additional 28.9% stake in JW CreaGene Co., Ltd. from group of sellers for KRW 30.7 billion. CI
JW Shinyak Corporation agreed to acquire an additional 28.9% stake in JW CreaGene Co., Ltd. from group of sellers for KRW 30.7 billion. CI
JW Shinyak Corporation announced that it has received KRW 25 billion in funding CI
JW Shinyak Corporation announced that it expects to receive KRW 25 billion in funding CI
More news
1 day+0.51%
1 week+2.76%
Current month-10.82%
1 month-14.86%
3 months-18.17%
6 months-17.66%
Current year-27.90%
More quotes
1 week
1 705.00
Extreme 1705
1 880.00
1 month
1 705.00
Extreme 1705
2 195.00
Current year
1 705.00
Extreme 1705
2 500.00
1 year
1 705.00
Extreme 1705
3 166.67
3 years
1 705.00
Extreme 1705
5 668.93
5 years
1 705.00
Extreme 1705
6 252.54
10 years
1 705.00
Extreme 1705
12 463.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 17-02-15
Independent Dir/Board Member 65 21-02-07
Members of the board TitleAgeSince
Chief Executive Officer 62 17-02-15
Independent Dir/Board Member 65 21-02-07
Director/Board Member 75 -
More insiders
Date Price Change Volume
24-04-23 1,788 +0.51% 66,336
24-04-22 1,779 +0.17% 47,224
24-04-19 1,776 -2.15% 108,593
24-04-18 1,815 +5.52% 416,159
24-04-17 1,720 -1.15% 112,390

End-of-day quote Korea S.E., April 22, 2024

More quotes
JW SHINYAK CORPORATION is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Company’s main products portfolio consists of antibiotics, anesthetics, respiratory remedies, urology remedies, cardiovascular remedies, allergy remedies, digestive remedies, anti-inflammatory drugs, antivirals as well as acne remedies, among others. In addition, it also involves in the provision of cosmetics, such as creams, cleansers, toners, essences, lotions and others.
More about the company
  1. Stock Market
  2. Equities
  3. A067290 Stock